Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
7.04
-0.29 (-3.96%)
Oct 29, 2025, 4:00 PM EDT - Market closed
DAWN Employees
Day One Biopharmaceuticals had 181 employees as of December 31, 2024. The number of employees increased by 26 or 16.77% compared to the previous year.
Employees
181
Change (1Y)
26
Growth (1Y)
16.77%
Revenue / Employee
$1,036,674
Profits / Employee
-$524,834
Market Cap
721.12M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 181 | 26 | 16.77% |
| Dec 31, 2023 | 155 | 34 | 28.10% |
| Dec 31, 2022 | 121 | 66 | 120.00% |
| Dec 31, 2021 | 55 | 35 | 175.00% |
| Dec 31, 2020 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DAWN News
- 8 days ago - Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025 - GlobeNewsWire
- 2 months ago - Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade) - Seeking Alpha
- 3 months ago - Day One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Day One Reports Second Quarter 2025 Financial Results and Corporate Progress - GlobeNewsWire
- 3 months ago - Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 - GlobeNewsWire
- 5 months ago - Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development - GlobeNewsWire
- 5 months ago - Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301 - Seeking Alpha
- 6 months ago - Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript - Seeking Alpha